Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-92328 in Relapsed/Refractory Multiple Myeloma
NCT04975399Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Trispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of ingitamig in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Dose-Limiting Toxicities, Maximum Tolerated Dose and 1 more. Started Oct 2021; status: terminated.
02
Drugs
ingitamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04975399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975399.